

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue:

MedPlus Health Services Limited

- | | |
|---|---|
| 1. Type of Issue (IPO/FPO) | IPO |
| 2. Issue Size (Rs. Cr) | INR 1,398.295 Cr |
| 3. Grade of issue along with name of the rating agency | |
| Name | NA |
| Grade | NA |
| 4. Subscription Level (Number of times) | The Offer was subscribed 52.8582 times (excluding the Anchor Investor Portion and after removing multiple and duplicate bids and technical rejection cases) * |

*Source-Minutes of Basis of Allotment dated December 20, 2021

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue	7.33%*
(ii) at the end of the 1st Quarter immediately after the listing of the issue ^{^^}	31.14%
(iii) at the end of 1st FY (March 31, 2022)**	32.21%
(iv) at the end of 2nd FY (March 31, 2023)**	32.65%
(v) at the end of 3rd FY (March 31, 2024) [^]	NA

(*) As a % of total post issue paid up capital as per Prospectus dated December 16, 2021

(^) QIB Holding not disclosed as reporting for relevant period / fiscal years has not been completed

^{^^} Shareholding Pattern filed with Stock Exchange for the quarter ended December 31, 2021

** Shareholding Pattern filed with Stock Exchange for the quarter ended March 31, 2022 & March 31, 2023

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated

(Rs in Crores)

Parameters	1st FY (March 31, 2022)**	2nd FY (March 31, 2023)**	3rd FY (March 31, 2024)*
Income from operations	3779.27	4557.75	N.A.
Net Profit for the period	94.71	50.10	N.A.
Paid-up equity share capital	23.86	23.86	N.A.
Reserves excluding revaluation reserves	1393.91	1467.31	N.A.

Standalone

(Rs in Crores)

Parameters	1st FY (March 31, 2022)**	2nd FY (March 31, 2023)**	3rd FY (March 31, 2024)*
Income from operations	145.71	213.92	N.A.
Net Profit for the period	5.57	5.54	N.A.
Paid-up equity share capital	23.86	23.86.	N.A.
Reserves excluding revaluation reserves	1088.92	1117.41	N.A.

* Financials not disclosed as reporting for the relevant fiscal years has not been completed.

** Source: Audited Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2022 & March 31, 2023

7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited and the National Stock Exchange of India Limited.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2023)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2024)*	N.A.

* Trading status not disclosed as reporting for the relevant fiscal years has not been completed

Source: Stock Exchange

8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	None	None
(ii) at the end of 2nd FY (March 31, 2023)*	None	None
(iii) at the end of 3rd FY (March 31, 2024)*	N.A.	N.A.

**Changes in directors not disclosed as reporting for relevant fiscal years has not been completed
However, until June 10, 2023 there has been no change on the Board*

9. Status of implementation of project/ commencement of commercial production

- (i) As disclosed in the offer document: NA
- (ii) Actual implementation: NA
- (iii) Reasons for delay in implementation, if any: NA

10. Status of utilization of issue proceeds

- (i) As disclosed in the offer document:

(Rs. In Million)

Particulars	Amount to be funded from the Net Proceeds	Estimated deployment		
		Fiscal 2022	Fiscal 2023	Fiscal 2024
Investment into our Material Subsidiary, Optival for funding working capital requirements of Optival	4,671.70	1,239.19	1,586.87	1,845.64
General corporate purposes	1,055.71	500	555.71	-
Total	5,727.41	1,739.19	2,142.58	1,845.64

(ii) Actual utilization:

(Rs. In Million)

Item Head	Amount as proposed in Offer Document	Amount utilized			Total unutilized amount as on (March 31,2023)
		As at the beginning of the quarter (January 1, 2023)	During the Quarter (Jan-Mar, 2023)	At the end of quarter (March 31,2023)	
Investment into our Material Subsidiary, Optival for funding working capital requirements of Optival	4,671.70	2,826.06	1845.64	4671.70	NIL
General Corporate Purpose [#]	1111.03	307.43	19.00	326.43	784.60
Total	5782.73	3133.49	1864.64	4998.13	784.60 *

Source: Monitoring Agency report dated May 15, 2023 for the Quarter ended March 31, 2023.

General Corporate Purpose Amount has increase due to reduction in Offer expense.

* Rs 78,46,00,603 is deployed into Fixed Deposit detailed and Rs. 3,51,97,745.06 is kept in Axis bank IPO Escrow Account

(iii) Reasons for deviation, if any: None

Source: Monitoring Agency report dated, May 15, 2023 for the Quarter ended March 31, 2023.

11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	None
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

Source: Monitoring Agency report dated, May 15, 2023 for the Quarter ended March 31, 2023.

12. Pricing Data

Issue Price (Rs.):	796/-
Designated Stock Exchange:	BSE
Listing Date:	December 23, 2021

Price parameters	At close of listing day (i.e. December 23, 2021)	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of 1st FY after the listing of the issue (March 31, 2022)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	1,120.85	1219.65	979.55	1010.25	1343	921
BSE SENSEX	57,315.28	59037.18	57989.3	58568.51	62245.43	47204.5
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2023)			As at the end of 3rd FY after the listing of the issue (March 31, 2024)*		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	651.15	1047.00	570.00	NA	NA	NA
BSE SENSEX	58991.52	63583.07	50921.22	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: BSE website

* Pricing Data not disclosed as reporting for the relevant fiscal years has not been completed

13. Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio		As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2022) ⁽⁴⁾	At the end of 2nd FY (March 31, 2023) ⁽⁴⁾	At the end of 3rd FY (March 31, 2024) ⁽²⁾
EPS	Issuer:	--	--	--	--
	Consolidated (Basic)	5.99	8.55	4.17	N.A
	Consolidated (Diluted)	5.75	8.52	4.17	N.A

	Peer Group ⁽³⁾ :	NA	NA	NA	NA
	Industry Avg:	NA	N.A	N.A	N.A
P/E	Issuer:	--	--	--	--
	Consolidated (Basic)	132.89	118.16	156.15	N.A
	Consolidated (Diluted)	138.43	118.57	156.15	N.A
	Peer Group ⁽³⁾ :	NA	NA	NA	NA
	Industry Composite:	NA	N.A	N.A	N.A
RoNW (%)	Issuer:	--	--	--	--
	Consolidated	8.74	0.50	3.36	N.A
	Peer Group ⁽³⁾ :	NA	NA	NA	NA
	Industry Composite:	NA	N.A	N.A	N.A
NAV	Issuer:	--	--	--	--
	Consolidated	65.37	93.28	124.99	N.A
	Peer Group ⁽³⁾ :	NA	NA	NA	NA
	Industry Avg:	NA	N.A	N.A	N.A

Notes:

- (1) Prospectus dated December 16, 2021
- (2) Not disclosed as the reporting for the relevant fiscal years has not been completed.
- (3) There are no listed companies in India that engage in a business similar to that of the Company. Accordingly, it is not possible to provide an industry comparison in relation to the Company
- (4) Source: Audited Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2022 & March 31, 2023

14. Any other material information

Particulars	Date
The Company has informed the Exchange that Mr. Parag Jain, Company Secretary and Compliance Officer has resigned w.e.f January 14, 2022. He has also ceased to be the Company Secretary of the Company's Subsidiary and Material Subsidiary.	January 13, 2022
The Company has informed the Exchange that Ms. Shilpi Keswani is appointed as the Company Secretary and Compliance Officer w.e.f January 15, 2022	January 13, 2022

The Company has informed the Exchange that the new Registered Office of the Company is H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad - 500037, Telangana, India with effect from 2nd May, 2022	May 3, 2022
The Company has informed the Exchange that Mr. Hemanth Kundavaram has resigned from the post of Chief Financial Officer ('CFO') and Key Managerial Personnel of the MedPlus Health Services Limited ('Company'), Optival Health Solutions Private Limited and Wynclark Pharmaceuticals Private Limited, subsidiaries of the Company. Mr. Kundavaram will continue to act as the CFO of the Company until Sunday, 5th June, 2022.	June 4, 2022
The Company has informed the Exchange that the Company has incorporated a wholly-owned subsidiary namely, 'MedPlus Insurance Brokers Private Limited'. As per the Certificate of Incorporation dated 14th July 2022 issued by the Registrar of Companies, Ministry of Corporate Affairs, the date of incorporation of wholly-owned subsidiary is 14th July, 2022.	July 15, 2022
The Company has informed the Exchange that Mr. Sujit Kumar Mahato, as Chief Financial Officer of the Company with effect from 11th November, 2022	November 11, 2022
The Company has informed the Exchange about the approval of the Scheme of Amalgamation ("Scheme") under Section 230 to Section 232 and other relevant provisions of the Companies Act, 2013 for amalgamation between MedPlus Health Services Limited ("Transferee Company") and MHS Pharmaceuticals Private Limited ("Transferor Company"), subject to requisite approvals	January 11, 2023
The Company has informed the exchange about the appointment of Mr. Manoj Kumar Srivastava as the Head Company Secretary and Compliance officer of the Company as required under Section 203 of the Companies Act, 2013, Regulation 6 of the SEBI (Listing Regulations and Disclosure Requirements), 2015, and Regulation 9(3) of the SEBI (Prohibition of Insider Trading) Regulations 2015, with effect from 30th March 2023 in place of Ms. Shilpi Keswani who has demitted the office of Company Secretary and Compliance officer of the company from the close of business hours of 30th March 2023.	March 30, 2023

Source- Stock Exchange Filings

All the above information has been updated till June 10, 2023 unless indicated otherwise